---
figid: PMC6373401__40263_2018_601_Fig1_HTML
figtitle: Neuroprotective mechanisms of antidiabetic drugs in the context of Parkinson’s
  disease dementia
organisms:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Macaca mulatta
- Canis lupus familiaris
organisms_ner:
- Rattus norvegicus
- Canis lupus familiaris
- Macaca mulatta
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC6373401
filename: 40263_2018_601_Fig1_HTML.jpg
figlink: /pmc/articles/PMC6373401/figure/Fig1/
number: F1
caption: Potential neuroprotective mechanisms of antidiabetic drugs in the context
  of Parkinson’s disease dementia. ChIs block ACh degradation by ChE allowing ACh
  to bind to either the mAChR or nicotinic receptors resulting in MAP kinase signalling.
  IGF-1 or insulin bind to the IR activating MAP kinase signalling, promoting cell
  growth and synaptic plasticity via BDNF, or the PI3 K/AKT signalling pathway, resulting
  in cell proliferation and survival via modulating multiple downstream targets including
  mTOR, GSK-3β, FoxO and NFκB. DPP-IV inhibitors block the degradation of GLP-1 by
  DDP-IV, promoting signalling, while GLP-1 analogues directly promote GLP-1R signalling,
  which increases cAMP activating of the aforementioned signalling pathways and also
  activates the PKA signalling pathway resulting in the activation of CREB and resultant
  gene transcription. Proinflammatory cytokines, which are elevated in Parkinson’s
  disease, such as TNFα and IL-1 promote pro-inflammatory cytokine release via NFκB
  signalling and can also inhibit insulin and IGF-1 signalling, resulting in the disruption
  of MAP kinase and PI3 K signalling. In contrast to this, glitazones can activate
  PPARγ, resulting in gene transcription of neuroprotective mediators. PGC-1α can
  bind to various transcription factors including PPARγ and exerts a neuroprotective
  effect. The insulin degrading enzyme can target α-syn, binding to α-syn oligomers
  inhibiting the formation of fibrils. α-syn alpha-synuclein, ACh acetylcholine, AKT
  protein kinase B, ChE cholinesterase, ChI cholinesterase inhibitor, BDNF brain-derived
  neurotrophic factor, cAMP cyclic adenosine monophosphate, CREB cyclic adenosine
  monophosphate response element-binding protein, DPP-IV dipeptidyl peptidase IV,
  FoxO forkhead box O, GLP-1 glucagon-like peptide-1, GLP1R glucagon-like peptide-1
  receptor, GSK3β glycogen synthase kinase-3β, IDE insulin degrading enzyme, IGF-1
  insulin growth factor-1, IL-1 interleukin-1, IR insulin receptor, mAChR muscarinic
  acetylcholine receptors, MAP mitogen-activated protein, mTOR mammalian target of
  rapamycin, NFκB nuclear factor-κB, PI3 K phosphatidylinositol 3 kinase pathway,
  PGC-1α PPARγ coactivator 1α, PKA protein kinase A, PPARγ proliferator-activated
  receptor-γ, TNFα tumour necrosis factor-α
papertitle: Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s
  Disease with an Emphasis on Diabetes-Related Pathways.
reftext: Holly Green, et al. CNS Drugs. 2019;33(2):143-160.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9506104
figid_alias: PMC6373401__F1
figtype: Figure
redirect_from: /figures/PMC6373401__F1
ndex: 8ef3a4d1-def4-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6373401__40263_2018_601_Fig1_HTML.html
  '@type': Dataset
  description: Potential neuroprotective mechanisms of antidiabetic drugs in the context
    of Parkinson’s disease dementia. ChIs block ACh degradation by ChE allowing ACh
    to bind to either the mAChR or nicotinic receptors resulting in MAP kinase signalling.
    IGF-1 or insulin bind to the IR activating MAP kinase signalling, promoting cell
    growth and synaptic plasticity via BDNF, or the PI3 K/AKT signalling pathway,
    resulting in cell proliferation and survival via modulating multiple downstream
    targets including mTOR, GSK-3β, FoxO and NFκB. DPP-IV inhibitors block the degradation
    of GLP-1 by DDP-IV, promoting signalling, while GLP-1 analogues directly promote
    GLP-1R signalling, which increases cAMP activating of the aforementioned signalling
    pathways and also activates the PKA signalling pathway resulting in the activation
    of CREB and resultant gene transcription. Proinflammatory cytokines, which are
    elevated in Parkinson’s disease, such as TNFα and IL-1 promote pro-inflammatory
    cytokine release via NFκB signalling and can also inhibit insulin and IGF-1 signalling,
    resulting in the disruption of MAP kinase and PI3 K signalling. In contrast to
    this, glitazones can activate PPARγ, resulting in gene transcription of neuroprotective
    mediators. PGC-1α can bind to various transcription factors including PPARγ and
    exerts a neuroprotective effect. The insulin degrading enzyme can target α-syn,
    binding to α-syn oligomers inhibiting the formation of fibrils. α-syn alpha-synuclein,
    ACh acetylcholine, AKT protein kinase B, ChE cholinesterase, ChI cholinesterase
    inhibitor, BDNF brain-derived neurotrophic factor, cAMP cyclic adenosine monophosphate,
    CREB cyclic adenosine monophosphate response element-binding protein, DPP-IV dipeptidyl
    peptidase IV, FoxO forkhead box O, GLP-1 glucagon-like peptide-1, GLP1R glucagon-like
    peptide-1 receptor, GSK3β glycogen synthase kinase-3β, IDE insulin degrading enzyme,
    IGF-1 insulin growth factor-1, IL-1 interleukin-1, IR insulin receptor, mAChR
    muscarinic acetylcholine receptors, MAP mitogen-activated protein, mTOR mammalian
    target of rapamycin, NFκB nuclear factor-κB, PI3 K phosphatidylinositol 3 kinase
    pathway, PGC-1α PPARγ coactivator 1α, PKA protein kinase A, PPARγ proliferator-activated
    receptor-γ, TNFα tumour necrosis factor-α
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Igf1
  - Tnf
  - Ide
  - Gcg
  - Tnfrsf1a
  - Pik3cg
  - Dpp4
  - Nfkb1
  - Rela
  - Akt1
  - Glp1r
  - Ppara
  - Creb1
  - Mtor
  - Ccne1
  - Bdnf
  - Il1r1
  - IGF1
  - TNF
  - IDE
  - IL1B
  - GCG
  - GLP1R
  - MTOR
  - BDNF
  - IL1R1
  - PRKACA
  - LCS1
  - FGFR3
  - ZGLP1
  - TNFRSF1A
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACB
  - PRKACG
  - SGSM3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - DPP4
  - FAP
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - AKT1
  - AKT2
  - AKT3
  - PPARGC1A
  - PPARA
  - PPARD
  - PPARG
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - BDNF-AS
  - Chrdl1
  - Ier2
  - Il1
  - Snca
  - Tnfrsf1b
  - Pik3r1
  - Ppargc1a
  - chl
  - chn
  - Chi
  - chic
  - che
  - Ace
  - egr
  - achi
  - emc
  - JIL-1
  - GlyP
  - mAChR-A
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - mapP
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Dif
  - dl
  - Rel
  - Akt
  - srl
  - CrebB
  - CrebA
  - foxo
  - Tor
  - CycE
  - cyc
  - Rivastigmine
  - donepezil
  - Ga
  - Sitagliptin
  - Glitazones
  - Cancer
---
